抗血小板药物是目前治疗缺血性心脏病的常用药物，主要包括氯吡格雷、阿司匹林，但易发生氯吡格雷抵抗、阿司匹林抵抗，而它们同属于抗凝治疗后血小板高反应性的范畴。遗传因素对血小板高反应性的影响至关重要。目前对血小板高反应性的治疗策略主要以个体化抗血小板治疗为主，常用的药物包括替格瑞洛、αIIbβ3拮抗剂、中药。总结了血小板高反应性的遗传因素和治疗策略的研究进展，旨在为血小板高反应性的治疗提供临床参考。

Antiplatelet drugs are currently commonly used in the treatment of ischemic heart disease, mainly including clopidogrel and aspirin. However, they are easy to develop clopidogrel resistance and aspirin resistance, both of which belong to high on-treatment platelet reactivity after anticoagulation therapy. The influence of genetic factors on high on-treatment platelet reactivity is crucial. At present, personalized antiplatelet therapy is the main treatment strategy for high on-treatment platelet reactivity, and commonly used drugs include ticagrelor, αIIbβ3 antagonists, and traditional Chinese medicine. This article summarizes the research progress on genetic factors and treatment strategies of high on-treatment platelet reactivity, to provide clinical reference for the treatment of high on-treatment platelet reactivity.

R973

安徽高校自然科学研究项目（KJ2021A0342）;安徽医科大学校科研基金项目（2022xkj100）;六安市科技计划项目（2022lakj034）